Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCR-ABL-positive cells in vitro

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Balabanov, Stefan ^a   Gontarewicz, Artur ^a   Keller, Gunhild ^a   Raddrizzani, Laura ^b   Braig, Melanie ^a   Bosotti, Roberta ^b   Moll, Jürgen ^b   Jost, Edgar ^c   Barett, Christine ^a   Rohe, Imke ^a   Bokemeyer, Carsten ^a   Holyoake, Tessa L ^d   Brümmendorf, Tim H ^a,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NERVIANO MEDICAL SCIENCES   (Italy)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; BREAST CANCER RESISTANCE PROTEIN; DANUSERTIB; IMATINIB; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; AURORA KINASE; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR PROTEIN;

ABCG2 ONCOGENE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE CONTROL; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; EFFUSION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; ONCOGENE; PROTEIN DOMAIN; CELL CLONE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MUTATION; PATHOLOGY; POLYPLOIDY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BENZAMIDES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERAZINES; POLYPLOIDY; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 79955592290     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019164     Document Type: Article

References (42)

1. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J, (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145: 913-923.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
3. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, et al. (2006) Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108: 1478-1484.
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
5. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, et al. (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190-2196.
6. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, et al. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698.
7. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, et al. (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92: 1641-1650.
8. Jorgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, et al. (2002) Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 99: 713-715.
9. Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, et al. (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21: 1267-1275.
10. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC, (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108: 1370-1373.
11. Ritchie E, Nichols G, (2006) Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy. Curr Cancer Drug Targets 6: 645-657.
12. Deininger M, Buchdunger E, Druker BJ, (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653.
13. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
14. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141.
15. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, et al. (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66: 11314-11322.
16. Keller G, Schafhausen P, Brummendorf TH Bosutinib. Recent Results Cancer Res 184: 119-127.
17. Goldman J, (2005) Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 12: 33-39.
18. Roeder I, Glauche I, (2008) Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia-insights from mathematical model analyses. J Mol Med 86: 17-27.
19. Glauche I, Horn M, Roeder I, (2007) Leukaemia stem cells: hit or miss? Br J Cancer 96: 677-678; author reply 679-680.
20. Dingli D, Michor F, (2006) Successful therapy must eradicate cancer stem cells. Stem Cells 24: 2603-2610.
21. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325.
22. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, et al. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107: 4532-4539.
23. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL, (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109: 4016-4019.
24. Konig H, Holyoake TL, Bhatia R, (2008) Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111: 2329-2338.
25. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, et al. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701-4707.
26. Gontarewicz A, Brummendorf TH, (2010) Danusertib (formerly PHA-739358)- A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor. Recent Results Cancer Res 184: 199-214.
27. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, et al. (2008) Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111: 4355-4364.
28. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, et al. (2007) Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 67: 7987-7990.
29. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, et al. (2007) PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6: 3158-3168.
30. von Bubnoff N, Barwisch S, Speicher MR, Peschel C, Duyster J, (2005) A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell Cycle 4: 400-406.
31. Jorge Cortes-Franco HD, Philippe Schafhausen, Tim H Brummendorf, Nicolas Boissel, Fabio Latini, Laura Capolongo, Bernard Laffranchi, and Silvia Comis, (2009) Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Blood (ASH Annual Meeting Abstracts) Nov 864.
32. Nicholson E, Holyoake T, (2009) The chronic myeloid leukemia stem cell. Clin Lymphoma Myeloma 9 (Suppl 4): S376-381.
33. Pellicano F, Holyoake TL, (2007) Stem cells in chronic myeloid leukaemia. Cancer Biomark 3: 183-191.
34. Thomas J, Wang L, Clark RE, Pirmohamed M, (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 3739-3745.
35. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, et al. (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942.
36. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, et al. (2007) Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21: 926-935.
37. Chu S, Holtz M, Gupta M, Bhatia R, (2004) BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103: 3167-3174.
38. Hiwase DK, White D, Zrim S, Saunders V, Melo JV, et al. (2010) Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia 24: 658-660.
39. Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, et al. (2007) Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109: 1701-1711.
40. Holyoake T, Jiang X, Eaves C, Eaves A, (1999) Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94: 2056-2064.
41. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
42. Wu Z IR, Gentleman R, Martinez Murillo F, Spencer F, (2004) A model based background adjustment for oligonucleotide expression arrays. John Hopkins University, Dept of Biostatistics Working papers Paper 1.